Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.
Ray-Coquard, I; Leary, A; Pignata, S; Cropet, C; González-Martin, A; Marth, C; Nagao, S; Vergote, I; Colombo, N; Mäenpää, J; Selle, F; Sehouli, J; Lorusso, D; Alia, EMG; Bogner, G; Yoshida, H; Lefeuvre-Plesse, C; Buderath, P; Mosconi, AM; Lortholary, A; Burges, A; Medioni, J; El-Balat, A; Rodrigues, M; Park-Simon, TW; Dubot, C; Denschlag, D; You, B; Pujade-Lauraine, E; Harter, P;
Ann Oncol. 2023;
Full papers/articles (Journal)

Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
Harter, P; Mouret-Reynier, MA; Pignata, S; Cropet, C; González-Martín, A; Bogner, G; Fujiwara, K; Vergote, I; Colombo, N; Nøttrup, TJ; Floquet, A; El-Balat, A; Scambia, G; Guerra Alia, EM; Fabbro, M; Schmalfeldt, B; Hardy-Bessard, AC; Runnebaum, I; Pujade-Lauraine, E; Ray-Coquard, I;
Gynecol Oncol. 2022; 164(2):254-264
Full papers/articles (Journal)

Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial.
Rinnerthaler, G; Gampenrieder, SP; Hackl, H; Steiner, M; Monzo-Fuentes, C; Melchardt, T; Magnes, T; Huemer, F; Westphal, T; Hufnagl, C; Hauser-Kronberger, C; Egle, A; Greil, R;
J Clin Med. 2020; 9(6):
Full papers/articles (Journal)

Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies.
da Silva, IP; Glitza, IC; Haydu, LE; Johnpulle, R; Banks, PD; Grass, GD; Goldinger, SMA; Smith, JL; Everett, AS; Koelblinger, P; Roberts-Thomson, R; Millward, M; Atkinson, VG; Guminski, A; Kapoor, R; Conry, RM; Carlino, MS; Wang, W; Shackleton, MJ; Eroglu, Z; Lo, S; Hong, AM; Long, GV; Johnson, DB; Menzies, AM
PIGM CELL MELANOMA R. 2019; 32(4): 553-563.
Full papers/articles (Journal)

[Predictive Value of OCT-Controlled Early Response of Macular Edema Secondary to Retinal Vein Occlusion After Intravitreal Bevacizumab Therapy].
Kourakos, V; Rauscher, A; Schmidbauer, J
KLIN MONATSBL AUGENH. 2019; 236(10): 1215-1222.
Full papers/articles (Journal)

Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in
Laurent-Puig, P; Grisoni, ML; Heinemann, V; Liebaert, F; Neureiter, D; Jung, A; Montestruc, F; Gaston-Mathe, Y; Thiébaut, R; Stintzing, S;
Clin Cancer Res. 2019; 25(1):134-141
Full papers/articles (Journal)

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Ray-Coquard, I; Pautier, P; Pignata, S; Pérol, D; González-Martín, A; Berger, R; Fujiwara, K; Vergote, I; Colombo, N; Mäenpää, J; Selle, F; Sehouli, J; Lorusso, D; Guerra Alía, EM; Reinthaller, A; Nagao, S; Lefeuvre-Plesse, C; Canzler, U; Scambia, G; Lortholary, A; Marmé, F; Combe, P; de Gregorio, N; Rodrigues, M; Buderath, P; Dubot, C; Burges, A; You, B; Pujade-Lauraine, E; Harter, P;
N Engl J Med. 2019; 381(25): 2416-2428.
Full papers/articles (Journal)

Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.
Stintzing, S; Wirapati, P; Lenz, HJ; Neureiter, D; Fischer von Weikersthal, L; Decker, T; Kiani, A; Kaiser, F; Al-Batran, S; Heintges, T; Lerchenmüller, C; Kahl, C; Seipelt, G; Kullmann, F; Moehler, M; Scheithauer, W; Held, S; Modest, DP; Jung, A; Kirchner, T; Aderka, D; Tejpar, S; Heinemann, V;
Ann Oncol. 2019; 30(11): 1796-1803.
Full papers/articles (Journal)

DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast Cancer
Gampenrieder, SP; Rinnerthaler, G; Hackl, H; Pulverer, W; Weinhaeusel, A; Ilic, S; Hufnagl, C; Hauser-Kronberger, C; Egle, A; Risch, A; Greil, R
THERANOSTICS. 2018; 8(8): 2278-2288.
Full papers/articles (Journal)

Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
Huemer, F; Thaler, J; Piringer, G; Hackl, H; Pleyer, L; Hufnagl, C; Weiss, L; Greil, R;
BMC Cancer. 2018; 18(1): 11
Full papers/articles (Journal)

Extensive Leptomeningeal Intracranial and Spinal Metastases in a Patient with a Supratentorial Glioblastoma Multiforme, IDH-Wildtype.
Schwartz, C; Romagna, A; Machegger, L; Weiss, L; Huemer, F; Fastner, G; Kleindienst, W; Serge, W; Greil, R; Winkler, PA;
World Neurosurg. 2018; 120:442-447
Case Reports

Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study.
Eisterer, W; Piringer, G; DE Vries, A; Öfner, D; Greil, R; Tschmelitsch, J; Samonigg, H; Sölkner, L; Gnant, M; Thaler, J;
Anticancer Res. 2017; 37(5):2683-2691
Full papers/articles (Journal)

Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer.
Gampenrieder, SP; Hufnagl, C; Brechelmacher, S; Huemer, F; Hackl, H; Rinnerthaler, G; Romeder, F; Monzo Fuentes, C; Morre, P; Hauser-Kronberger, C; Mlineritsch, B; Greil, R;
Pharmacogenomics J. 2017; 17(4):344-350
Full papers/articles (Journal)

Antiangiogenic therapy in breast cancer.
Gampenrieder, SP; Westphal, T; Greil, R;
Memo. 2017; 10(4):194-201
Reviews

Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia : A case report.
Huemer, F; Dejaco, M; Grabmer, C; Melchardt, T; Neureiter, D; Mayer, G; Egle, A; Greil, R; Weiss, L;
Wien Klin Wochenschr. 2017; 129(3-4):-144
Case Reports

Update on squamous cell carcinoma of the head and neck: ASCO annual meeting 2017.
Magnes, T; Egle, A; Greil, R; Melchardt, T;
MEMO-MAG EUR MED ONC. 2017; 10(4): 220-223.
Reviews

[Diagnosis and Management of Vestibular Schwannomas - An Interdisciplinary Challenge].
Rosahl, S; Bohr, C; Lell, M; Hamm, K; Iro, H;
Laryngorhinootologie. 2017; 96(S 01): S15-S182.
Full papers/articles (Journal)

Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients - AGMT_GASTRIC-3.
Wöll, E; Thaler, J; Keil, F; Gruenberger, B; Hejna, M; Eisterer, W; Fridrik, MA; Ulmer, H; Trommet, V; Huemer, F; Weiss, L; Greil, R;
Anticancer Res. 2017; 37(10): 5553-5558.
Full papers/articles (Journal)

The VEGF rise in blood of bevacizumab patients is not based on tumor escape but a host-blockade of VEGF clearance.
Alidzanovic, L; Starlinger, P; Schauer, D; Maier, T; Feldman, A; Buchberger, E; Stift, J; Koeck, U; Pop, L; Gruenberger, B; Gruenberger, T; Brostjan, C;
Oncotarget. 2016; 7(35):5719-57212
Full papers/articles (Journal)

Chemotherapy of colorectal liver metastases induces a rapid rise in intermediate blood monocytes which predicts treatment response.
Schauer, D; Starlinger, P; Alidzanovic, L; Zajc, P; Maier, T; Feldman, A; Padickakudy, R; Buchberger, E; Elleder, V; Spittler, A; Stift, J; Pop, L; Gruenberger, B; Gruenberger, T; Brostjan, C;
Oncoimmunology. 2016; 5(6):e1160185
Full papers/articles (Journal)

[Position paper on medication-related osteonecrosis of the jaw (MRONJ)].
Svejda, B; Muschitz, C; Gruber, R; Brandtner, C; Svejda, C; Gasser, RW; Santler, G; Dimai, HP
Wien Med Wochenschr. 2016; 166(1-2):68-74
Full papers/articles (Journal)

Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer.
Stintzing, S; Zhang, W; Heinemann, V; Neureiter, D; Kemmerling, R; Kirchner, T; Jung, A; Folwaczny, M; Yang, D; Ning, Y; Sebio, A; Stremitzer, S; Sunakawa, Y; Matsusaka, S; Yamauchi, S; Loupakis, F; Cremolini, C; Falcone, A; Lenz, HJ;
Mol Cancer Ther. 2015; 14(10): 2374-2381.
Full papers/articles (Journal)

Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses.
Brodowicz, T; Lang, I; Kahan, Z; Greil, R; Beslija, S; Stemmer, SM; Kaufman, B; Petruzelka, L; Eniu, A; Anghel, R; Koynov, K; Vrbanec, D; Pienkowski, T; Melichar, B; Spanik, S; Ahlers, S; Messinger, D; Inbar, MJ; Zielinski, C;
Br J Cancer. 2014; 111(11): 2051-2057.
Full papers/articles (Journal)

Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: results from a retrospective matched-pair analysis.
Gampenrieder, SP; Romeder, F; Muß, C; Pircher, M; Ressler, S; Rinnerthaler, G; Bartsch, R; Sattlberger, C; Mlineritsch, B; Greil, R;
Anticancer Res. 2014; 34(1): 227-233.
Full papers/articles (Journal)

Liver toxicity during temozolomide chemotherapy caused by Chinese herbs.
Melchardt, T; Magnes, T; Weiss, L; Grundbichler, M; Strasser, M; Hufnagl, C; Moik, M; Greil, R; Egle, A;
BMC COMPLEM ALTERN M. 2014; 14: 115
Case Reports

AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
Gianni, L; Romieu, GH; Lichinitser, M; Serrano, SV; Mansutti, M; Pivot, X; Mariani, P; Andre, F; Chan, A; Lipatov, O; Chan, S; Wardley, A; Greil, R; Moore, N; Prot, S; Pallaud, C; Semiglazov, V;
J Clin Oncol. 2013; 31(14):1719-1725
Full papers/articles (Journal)

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings.
Kubicka, S; Greil, R; André, T; Bennouna, J; Sastre, J; Van Cutsem, E; von Moos, R; Osterlund, P; Reyes-Rivera, I; Müller, T; Makrutzki, M; Arnold, D;
Ann Oncol. 2013; 24(9):2342-2349
Full papers/articles (Journal)

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
Lang, I; Brodowicz, T; Ryvo, L; Kahan, Z; Greil, R; Beslija, S; Stemmer, SM; Kaufman, B; Zvirbule, Z; Steger, GG; Melichar, B; Pienkowski, T; Sirbu, D; Messinger, D; Zielinski, C;
Lancet Oncol. 2013; 14(2):125-133
Full papers/articles (Journal)

Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer.
Lang, I; Inbar, MJ; Kahán, Z; Greil, R; Beslija, S; Stemmer, SM; Kaufman, B; Zvirbule, Z; Steger, GG; Messinger, D; Brodowicz, T; Zielinski, C;
Eur J Cancer. 2012; 48(17):3140-3149
Full papers/articles (Journal)

Influence of the American ODAC statement on Austrian bevacizumab prescribing practice for metastatic breast cancer.
Preusser, M; Fülöp, G; Berghoff, AS; Heinzl, H; Steger, GG; Greil, R; Zielinski, CC; Bartsch, R;
Oncologist. 2012; 17(7): e13-e17.
Full papers/articles (Journal)

Preoperative treatment with capecitabine, bevacizumab and radiotherapy for primary locally advanced rectal cancer--a two stage phase II clinical trial.
Resch, G; De Vries, A; Öfner, D; Eisterer, W; Rabl, H; Jagoditsch, M; Gnant, M; Thaler, J;
Radiother Oncol. 2012; 102(1): 10-13.
Full papers/articles (Journal)

Histiocytic sarcoma - targeted therapy: novel therapeutic options? A series of 4 cases.
Schlick, K; Aigelsreiter, A; Pichler, M; Reitter, S; Neumeister, P; Hoefler, G; Beham-Schmid, C; Linkesch, W
Onkologie. 2012; 35(7-8):447-450
Case Reports

O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma.
Hutterer, M; Nowosielski, M; Putzer, D; Waitz, D; Tinkhauser, G; Kostron, H; Muigg, A; Virgolini, IJ; Staffen, W; Trinka, E; Gotwald, T; Jacobs, AH; Stockhammer, G;
J Nucl Med. 2011; 52(6): 856-864.
Full papers/articles (Journal)

Complement factor H Y402H gene polymorphism and response to intravitreal bevacizumab in exudative age-related macular degeneration.
Nischler, C; Oberkofler, H; Ortner, C; Paikl, D; Riha, W; Lang, N; Patsch, W; Egger, SF;
ACTA OPHTHALMOL. 2011; 89(4): e344-e349.
Full papers/articles (Journal)

Contrast sensitivity after intravitreal antivascular endothelial growth factor therapy for myopic choroidal neovascularization.
Moussa, S; Ansari-Shahrezaei, S; Smretschnig, E; Hagen, S; Steindl-Kuscher, K; Krebs, I; Binder, S
Graefes Arch Clin Exp Ophthalmol. 2010; 248(8):1087-1090
Full papers/articles (Journal)

Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study.
Greil, R; Moik, M; Reitsamer, R; Ressler, S; Stoll, M; Namberger, K; Menzel, C; Mlineritsch, B;
EJSO-EUR J SURG ONC. 2009; 35(10): 1048-1054.
Full papers/articles (Journal)

Successful antiangiogenic combination therapy for pseudomyxoma peritonei with bevacizumab and capecitabine.
Sun, WL; Hutarew, G; Gradl, J; Gratzl, M; Denz, H; Fiegl, M;
Cancer Biol Ther. 2009; 8(15):1459-1462
Full papers/articles (Journal)